Linneo Health awarded EU Good Manufacturing Practice (GMP)

Linneo Health awarded EU Good Manufacturing Practice (GMP) Part I license

• Certification additional expands current providing, enabling Linneo Health to fabricate completed dosage types alongside dried flowers and APIs

Madrid, Spain, 13^th September 2022: Linneo Health, a world chief within the analysis, cultivation and provide of hashish to enhance human well being and wellbeing, at this time pronounces that its dried flower facility has been awarded the EU Good Manufacturing Practice (GMP) Part I license by the Spanish Agency of Medicines and Medical Products (Agencia Española de Medicamentos y Productos Sanitarios or AEMPS), for the manufacture of intermediates and completed medicinal hashish merchandise. This new certification vastly extends Linneo’s current Part II license for the manufacture of Active Pharmaceutical Ingredients (APIs).

EU-GMP certification is recognised by all medication regulatory companies inside the EU, in addition to the vast majority of main companies over the world.

This certification additionally brings further packaging capabilities for Linneo’s dried flower merchandise, permitting Linneo to fabricate in a variety of codecs and sizes, tailor-made to buyer wants. Another profit is that it avoids the necessity for the native launch of dry flowers, so prospects shouldn’t have to undergo the method of analyzing the product domestically. This certification demonstrates Linneo’s unrivalled deal with high quality and medical requirements.

Don Bellamy, Chief Executive Officer of Linneo Health, mentioned: “I’m delighted to share the news of our GMP Part I certification, which marks a further milestone for Linneo. Obtaining EU GMP Part I certification of our dried flower facilities perfectly complements our existing Part II license. As our customers and their requirements develop, Linneo is perfectly positioned as the supplier of choice to provide high quality cannabis products, tailored to our customers’ needs.”

Maria José Garcia, Quality and RA Director of Linneo Health, added: “At Linneo we work continuously to ensure our facilities meet the strictest EU GMP requirements. This certification represents a huge, combined effort of the Linneo team. We are excited to be able to provide our customers with an expanded product offering – our excellent cannabis dried flower, APIs and now finished dosage forms.”

– ENDS –

Enquiries:

Linneo Health                                                 
Don Bellamy, CEO                                        Tel: +34 91 700 20 90

Consilium Strategic Communications                         
Amber Fennell / David Daley                                Tel: +44 (0) 20 3709 5700
[email protected]

About Linneo Health

Linneo Health is a Europe primarily based, world chief within the analysis, EU-GMP licensed manufacture and provide of medicinal hashish flowers, extracts and merchandise to pharmaceutical companions creating revolutionary cannabis-based therapies for sufferers in want. The world’s solely vertically built-in medicinal hashish provider, no different firm has Linneo’s 90-year heritage within the manufacturing and motion of managed substances. Linneo is optimally positioned to deal with the wants of its prospects by each stage of product improvement, regulation and dealing with.

Linneo Health is setting the benchmark for requirements and customer support in medicinal hashish. Through ongoing funding in some of the superior high quality management laboratories in Europe, and by making use of industry-leading cultivation methods, Linneo is the trusted associate to deal with the wants of shoppers at this time and, with vital enlargement capabilities, the calls for of tomorrow. With an unrivalled deal with high quality and pushed by the agency perception that folks all over the world should be handled with hashish medication of the best customary, Linneo brings innovative innovation in medicinal hashish to companions, to ship higher affected person outcomes and enhance lives. www.linneohealth.com